RESPONSE OF THE LAMBERT-EATON MYASTHENIC SYNDROME TO TREATMENT OF ASSOCIATED SMALL-CELL LUNG-CARCINOMA
RESPONSE OF THE LAMBERT-EATON MYASTHENIC SYNDROME TO TREATMENT OF ASSOCIATED SMALL-CELL LUNG-CARCINOMA
复制标题
DOI：
10.1212/wnl.40.10.1552
复制
发表时间：
1990-10-01
期刊：
影响因子：
9.9
通讯作者：
SPIRO, SG
中科院分区：
文献类型：
--
作者：
CHALK, CH;MURRAY, NMF;SPIRO, SG
我们评估了16例与组织学证实的小细胞癌（SCC）相关的Lambert-Eaton肌无力综合征（LEMS）患者的结局。13例患者接受了特异性肿瘤治疗（化疗、放疗或切除术），大多数患者还接受了LEMS的药物和免疫治疗。肿瘤治疗后存活超过2个月的11例患者中有7例显示出显著的神经功能改善（1例患者在7年时完全缓解）; 11例患者中有3例的改善是暂时的。在最终随访时，疾病严重程度的EMG指数（小指展肌复合肌肉动作电位振幅）显著增加（p < 0.01; n = 11）。治疗前振幅> 3.0 mV是一个良好的预后指标。我们的结论是，在SCC LEMS的联合治疗方法通常会导致神经功能的改善。
We evaluated the outcome in 16 patients with Lambert-Eaton myasthenic syndrome (LEMS) associated with histologically verified small-cell carcinoma (SCC). Thirteen patients received specific tumor therapy (chemotherapy, radiation therapy, or resection) and most also received pharmacologic and immunologic treatment for LEMS. Seven of 11 patients surviving for more than 2 months after tumor therapy showed substantial neurologic improvement (1 patient being in complete remission at 7 years); in 3 of 11 improvement was transient. An EMG index of disease severity (compound muscle action potential amplitude in abductor digiti minimi) was significantly increased at final follow-up (p < 0.01; n = 11). A pretreatment amplitude > 3.0 mV was a good prognostic sign. We conclude that a combined treatment approach in SCC-LEMS usually results in neurologic improvement.